Carle F. Paul

Toulouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 200 publications

Maintenance of clinical response to anifrolumab in cutaneous lupus erythematosus after dose spacing.

Maintenance of clinical response to anifrolumab in cutaneous lupus erythematosus after dose spacing.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 02, 2026

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Journal: American journal of clinical dermatology
Published: June 18, 2026

Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis.

Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 22, 2026

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

Journal: The Journal of investigative dermatology
Published: May 18, 2026

The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases.

The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases.

Journal: The journal of allergy and clinical immunology. In practice
Published: April 15, 2026

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.

Journal: American journal of clinical dermatology
Published: January 15, 2026

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.

Journal: Annals of the rheumatic diseases
Published: December 23, 2025

JEADV 2024-2026: From innovation to better patient care.

JEADV 2024-2026: From innovation to better patient care.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 08, 2025

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema.

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema.

Journal: Allergy
Published: October 26, 2025

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Journal: American journal of clinical dermatology
Published: September 15, 2025

Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ.

Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 03, 2025

What do we need to know to enhance treatment for multimorbid older patients?-Results from the PACT study.

What do we need to know to enhance treatment for multimorbid older patients?-Results from the PACT study.

Journal: Aging & mental health
Published: February 17, 2025
Showing 1-12 of 200

Last Updated: 09/26/2026